Cell harvesting is one of the highest-volume centrifuge applications in pharmaceutical and biopharmaceutical laboratories, separating cultured cells from growth medium at the end of a production run, fermentation cycle, or bioanalytical preparation. The relative centrifugal force (RCF), run temperature, acceleration and deceleration rate, and run duration applied during this step directly determine cell viability, recovery yield, and the quality attributes of any downstream product. This article covers the RCF requirements for the cell types most commonly processed in pharma environments, the temperature and ramp parameters that protect product integrity, and the validation and documentation requirements that apply when cell harvesting is performed under good manufacturing practice (GMP).
RCF and speed selection for pharma cell harvesting
The RCF used must be matched to the mechanical fragility of the target cell type. Using too low an RCF produces incomplete recovery; using too high an RCF damages cell membranes, releases intracellular contents, and reduces the viability of cells intended for downstream culture or processing.
Mammalian cell lines — including Chinese hamster ovary (CHO) cells, HEK293 cells, Vero cells, and hybridomas — are mechanically fragile and require gentle conditions. For this group, the standard RCF range is 200–500 × g for 10–15 minutes, sufficient to produce a compact pellet while preserving viability. Higher forces are occasionally used for secondary centrifugation to remove residual cells from clarified supernatant, but the primary harvest should not exceed 500 × g for lines with documented shear sensitivity.
Microbial cells tolerate significantly higher forces. Escherichia coli and related gram-negative bacteria are typically processed at 4,000–8,000 × g for 15–20 minutes; the higher end of this range is used when high-purity pellets are required and the membrane integrity of the harvested cells is not a downstream concern. Saccharomyces cerevisiae and other yeast species are harvested at 3,000–5,000 × g for 5–10 minutes, with the thicker cell wall providing mechanical protection not available to mammalian lines.
| Cell type | Typical RCF | Temperature | Run duration |
|---|---|---|---|
| Mammalian (CHO, HEK293, hybridomas) | 200–500 × g | 4°C | 10–15 min |
| Vero cells | 200–400 × g | 4°C | 10–15 min |
| E. coli and gram-negative bacteria | 4,000–8,000 × g | 4°C | 15–20 min |
| Yeast (S. cerevisiae) | 3,000–5,000 × g | 4°C | 5–10 min |
| Insect cells (Sf9, Sf21) | 500–1,000 × g | 4°C | 10–15 min |
RCF must always be expressed in × g — not revolutions per minute (RPM) — in formally validated pharma protocols. The same RPM on two rotors with different radii produces different centrifugal forces; specifying RPM without rotor radius information makes a protocol non-transferable between instruments and non-compliant with GMP documentation standards.
Temperature control and ramp parameters
Temperature is the second most critical parameter in pharma cell harvesting. Most biologics production runs use 4°C to minimize proteolytic degradation of secreted products, limit metabolic activity during the separation, and reduce the risk of product denaturation. For refrigerated centrifuges, both the rotor and the bowl should be pre-cooled to the set temperature before samples are loaded — a room-temperature rotor will briefly warm samples during the initial acceleration phase, introducing a thermal excursion that may not appear in run logs but affects sample integrity in temperature-sensitive applications.
Pre-cooling time varies by centrifuge model and total rotor mass; the manufacturer's guidance should be followed, and temperature should be verified with a calibrated reference thermometer before sample loading begins.
Acceleration and deceleration rates are equally important and are often absent from early-stage cell harvesting protocols. For fragile mammalian cell lines, abrupt acceleration generates transient shear forces that damage cells before the target RCF is even reached. A gradual, controlled ramp rate — set to the slowest option compatible with run throughput requirements — is the standard approach for mammalian cell harvesting, with deceleration matching or slower than the acceleration profile to prevent pellet resuspension.
Lab Quality Management Certificate
The Lab Quality Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
For microbial harvesting, ramp rates are less critical to cell integrity but still affect pellet compaction and run-to-run reproducibility. Slower deceleration produces more densely packed pellets that are less prone to disturbance during supernatant removal — a practical consideration when maximizing yield from high-density bacterial cultures.
Run time must be validated against the specific cell density and vessel volume used in production. For a given RCF, cells in a concentrated suspension require longer than those in a dilute suspension to fully pellet. Protocol validation should establish the minimum run time that achieves the target recovery yield across the expected range of input cell densities, not just at the nominal density.
Centrifuge selection for pharma-scale cell harvesting
The centrifuge selected must match both the volume requirements and the GMP documentation expectations of the application. Benchtop refrigerated centrifuges with swinging-bucket rotors are the standard choice for small-scale mammalian applications — up to approximately 250–500 mL per run — because swinging-bucket geometry produces soft, loosely packed pellets that resuspend easily and impose less mechanical stress during sedimentation than fixed-angle equivalents. Fixed-angle rotors are preferred for microbial and yeast harvest where pellet density and compaction matter more than ease of resuspension.
Interested in lab tools and techniques?
For larger volumes — multiple liters per run in pilot-scale or manufacturing operations — floor-standing high-capacity centrifuges are used, with some biopharma applications employing continuous-flow centrifugation for very large culture volumes where batch centrifugation is impractical. Regardless of scale, any centrifuge used in a GMP process must be included in the site's equipment inventory, qualified to the appropriate level, and maintained under a documented preventive maintenance program. The broader framework of centrifuge types, rotor selection, and RCF calibration that underpins equipment selection is covered in Lab Manager's complete guide to lab centrifuge types and operating best practices.
Validating cell harvesting centrifuge protocols under GMP
In regulated pharma environments governed by FDA 21 CFR Part 211 and aligned with International Council for Harmonisation (ICH) guidance, cell harvesting protocols must be formally validated before use in production. Validation demonstrates that the protocol consistently produces pellets and supernatants meeting predefined acceptance criteria for recovery, viability, and — where the supernatant contains the product of interest — quality attributes such as purity, activity, and aggregate content.
The validated protocol must specify, at minimum:
- Centrifuge model and rotor type, with equipment qualification reference number
- Target RCF and acceptable tolerance range
- Acceleration and deceleration ramp rates
- Set temperature and pre-cool verification method
- Run duration and any hold conditions after centrifugation
- Maximum elapsed time between culture termination and completion of the harvest
- Acceptance criteria for viability, recovery yield, and product quality attributes
Any change to a validated protocol — including a change of centrifuge model, rotor type, or run vessel — triggers a change control review and may require partial or full revalidation depending on the risk assessment. For scale-up from development to manufacturing scale, the change in centrifuge platform and rotor geometry is almost always classified as a significant change requiring full revalidation of recovery, viability, and critical quality attribute outcomes before the new configuration can be approved for production use.
Documentation and deviation management
Every cell harvesting run in a GMP environment must be fully documented in the batch record, including the centrifuge equipment identifier, rotor identifier, actual RCF achieved, run temperature, start and end times, and operator identity. Deviations from the validated parameters — including any imbalance shutoff, temperature excursion, or run time outside the validated range — must be captured and investigated before the harvested material advances to the next process step. A pattern of repeated deviations in the same parameter is itself a process signal that warrants investigation beyond the handling of individual events.
Operator qualification should include documented training on the centrifuge standard operating procedure (SOP), competency assessment covering rotor loading, balance verification, parameter entry, and post-run inspection, and a training record retained in the operator's file. In environments where multiple operators perform the same process, inter-operator variability should be assessed during validation to confirm that yields and quality attributes are consistent regardless of who performs the harvest.
Setting cell harvesting parameters that hold across production
Cell harvesting is one of the few process steps where a parameter error — the wrong RCF, an uncontrolled temperature, a missed ramp rate — can simultaneously reduce yield, impair cell viability, and introduce product quality failures that are difficult to trace back to the separation step. Matching RCF to cell type, controlling temperature from pre-cool through to run completion, specifying ramp rates appropriate for cell fragility, and validating the complete parameter set before GMP use are the disciplines that convert a routine centrifuge step into a controlled, reproducible, and defensible manufacturing operation.
References
- U.S. Food and Drug Administration. Current Good Manufacturing Practice for Finished Pharmaceuticals. 21 CFR Part 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
- International Council for Harmonisation. (1997). Q5D: Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. ICH. https://database.ich.org/sites/default/files/Q5D%20Guideline.pdf
- U.S. Food and Drug Administration. (2011). Process Validation: General Principles and Practices. FDA Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
